34.09
1.28%
-0.4425
After Hours:
34.09
0.0011
+0.00%
ALPS Medical Breakthroughs ETF stock is currently priced at $34.09, with a 24-hour trading volume of 1,659.
It has seen a -1.28% decreased in the last 24 hours and a +5.37% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $34.51 pivot point. If it approaches the $34.34 support level, significant changes may occur.
Previous Close:
$34.53
Open:
$34.4182
24h Volume:
1,659
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.89%
1M Performance:
+5.37%
6M Performance:
+33.48%
1Y Performance:
+7.00%
ALPS Medical Breakthroughs ETF Stock (SBIO) Company Profile
Name
ALPS Medical Breakthroughs ETF
Sector
Industry
Phone
844-234-5852
Address
-
ALPS Medical Breakthroughs ETF Stock (SBIO) Latest News
Cboe Global Markets surpasses 1,000 ETFs worldwide - The Globe and Mail
The Globe and Mail
ETF Issuer: Bristol Gate Capital Partners Inc. - The Globe and Mail
The Globe and Mail
9 Best Biotech ETFs for 2024 - MSN
MSN
Canadian Ether ETFs Opportunity if SEC approves Spot Ether in U.S. - The Globe and Mail
The Globe and Mail
5 Sector ETFs That Beat the Market in April - Yahoo Movies Canada
Yahoo Movies Canada
Best ETF Areas of Last Week - Yahoo Canada Shine On
Yahoo Canada Shine On
ALPS Medical Breakthroughs ETF Stock (SBIO) Financials Data
There is no financial data for ALPS Medical Breakthroughs ETF (SBIO). Check out other stocks for more information.
About ALPS Medical Breakthroughs ETF
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM.
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.
Cap:
|
Volume (24h):